GB0031107D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0031107D0
GB0031107D0 GBGB0031107.6A GB0031107A GB0031107D0 GB 0031107 D0 GB0031107 D0 GB 0031107D0 GB 0031107 A GB0031107 A GB 0031107A GB 0031107 D0 GB0031107 D0 GB 0031107D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0031107.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0031107.6A priority Critical patent/GB0031107D0/en
Publication of GB0031107D0 publication Critical patent/GB0031107D0/en
Priority to TW090131348A priority patent/TWI292759B/zh
Priority to ARP010105863A priority patent/AR035522A1/es
Priority to DE60124302T priority patent/DE60124302T2/de
Priority to AU2002246713A priority patent/AU2002246713B2/en
Priority to JP2002562729A priority patent/JP4209681B2/ja
Priority to ES01994305T priority patent/ES2274914T3/es
Priority to IL15643601A priority patent/IL156436A0/xx
Priority to MXPA03005699A priority patent/MXPA03005699A/es
Priority to MYPI20015760A priority patent/MY136685A/en
Priority to SI200130672T priority patent/SI1343773T1/sl
Priority to PL01365797A priority patent/PL365797A1/xx
Priority to HK04101319.8A priority patent/HK1059925B/en
Priority to BR0116370-1A priority patent/BR0116370A/pt
Priority to HU0400837A priority patent/HUP0400837A3/hu
Priority to US10/451,313 priority patent/US7105551B2/en
Priority to CZ20031737A priority patent/CZ20031737A3/cs
Priority to NZ526543A priority patent/NZ526543A/en
Priority to KR1020037008392A priority patent/KR100815022B1/ko
Priority to CA002432188A priority patent/CA2432188A1/en
Priority to AT01994305T priority patent/ATE344253T1/de
Priority to CNB018223095A priority patent/CN1252057C/zh
Priority to EP01994305A priority patent/EP1343773B1/en
Priority to DK01994305T priority patent/DK1343773T3/da
Priority to PCT/US2001/049230 priority patent/WO2002062774A1/en
Priority to PT01994305T priority patent/PT1343773E/pt
Priority to IL156436A priority patent/IL156436A/en
Priority to ZA200304679A priority patent/ZA200304679B/en
Priority to NO20032801A priority patent/NO20032801L/no
Priority to US11/465,135 priority patent/US7439259B2/en
Priority to CY20071100032T priority patent/CY1105915T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0031107.6A 2000-12-20 2000-12-20 Chemical compounds Ceased GB0031107D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds
TW090131348A TWI292759B (en) 2000-12-20 2001-12-18 Novel compound useful in the treatment of human peroxisome proliferator activate receptors (hppars) related diseases or conditions
ARP010105863A AR035522A1 (es) 2000-12-20 2001-12-18 Compuestos derivados de fenol, composiciones farmaceuticas, su uso y metodo de tratamiento
PT01994305T PT1343773E (pt) 2000-12-20 2001-12-19 Derivados tiazole para o tratamento de distúrbios relacionados com a ppar
HU0400837A HUP0400837A3 (en) 2000-12-20 2001-12-19 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
KR1020037008392A KR100815022B1 (ko) 2000-12-20 2001-12-19 Ｐｐａｒ 관련 질환을 치료하기 위한 티아졸 유도체
JP2002562729A JP4209681B2 (ja) 2000-12-20 2001-12-19 Ｐｐａｒ関連障害治療用のチアゾール誘導体
ES01994305T ES2274914T3 (es) 2000-12-20 2001-12-19 Derivados de tiazol para tratar trastornos relacionados con ppar.
IL15643601A IL156436A0 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders
MXPA03005699A MXPA03005699A (es) 2000-12-20 2001-12-19 Derivados de tiazol para tratar trastornos relacionados con ppar.
MYPI20015760A MY136685A (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders
SI200130672T SI1343773T1 (sl) 2000-12-20 2001-12-19 Tiazolni derivati za zdravljenje motenj v zvezi s PPAR
PL01365797A PL365797A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders
HK04101319.8A HK1059925B (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders
BR0116370-1A BR0116370A (pt) 2000-12-20 2001-12-19 Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE60124302T DE60124302T2 (de) 2000-12-20 2001-12-19 Thiazolderivate zur behandlung von ppar-lierte krankheiten
US10/451,313 US7105551B2 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating PPAR related disorders
CZ20031737A CZ20031737A3 (cs) 2000-12-20 2001-12-19 Thiazolové deriváty
NZ526543A NZ526543A (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating PPAR related disorders
AU2002246713A AU2002246713B2 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating PPAR related disorders
CA002432188A CA2432188A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders
AT01994305T ATE344253T1 (de) 2000-12-20 2001-12-19 Thiazolderivate zur behandlung von ppar-lierte krankheiten
CNB018223095A CN1252057C (zh) 2000-12-20 2001-12-19 用于治疗与paar有关的疾病的噻唑衍生物
EP01994305A EP1343773B1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for traeing ppar related disorders
DK01994305T DK1343773T3 (da) 2000-12-20 2001-12-19 Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
PCT/US2001/049230 WO2002062774A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders
IL156436A IL156436A (en) 2000-12-20 2003-06-12 Thiazole derivatives and pharmaceutical preparations containing them
ZA200304679A ZA200304679B (en) 2000-12-20 2003-06-17 Thiazole derivatives for treating PPAR related disorders.
NO20032801A NO20032801L (no) 2000-12-20 2003-06-19 Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
US11/465,135 US7439259B2 (en) 2000-12-20 2006-08-17 Thiazole derivatives for treating PPAR related disorders
CY20071100032T CY1105915T1 (el) 2000-12-20 2007-01-10 Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0031107D0 true GB0031107D0 (en) 2001-01-31

Family

ID=9905492

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0031107.6A Ceased GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds

Country Status (27)

Country Link
EP (1) EP1343773B1 (enExample)
JP (1) JP4209681B2 (enExample)
KR (1) KR100815022B1 (enExample)
CN (1) CN1252057C (enExample)
AR (1) AR035522A1 (enExample)
AT (1) ATE344253T1 (enExample)
AU (1) AU2002246713B2 (enExample)
BR (1) BR0116370A (enExample)
CA (1) CA2432188A1 (enExample)
CY (1) CY1105915T1 (enExample)
CZ (1) CZ20031737A3 (enExample)
DE (1) DE60124302T2 (enExample)
DK (1) DK1343773T3 (enExample)
ES (1) ES2274914T3 (enExample)
GB (1) GB0031107D0 (enExample)
HU (1) HUP0400837A3 (enExample)
IL (2) IL156436A0 (enExample)
MX (1) MXPA03005699A (enExample)
MY (1) MY136685A (enExample)
NO (1) NO20032801L (enExample)
NZ (1) NZ526543A (enExample)
PL (1) PL365797A1 (enExample)
PT (1) PT1343773E (enExample)
SI (1) SI1343773T1 (enExample)
TW (1) TWI292759B (enExample)
WO (1) WO2002062774A1 (enExample)
ZA (1) ZA200304679B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
IL152979A0 (en) 2000-05-26 2003-06-24 Nippon Shinyaku Co Ltd Heterocyclic compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
HRP20040098B1 (en) * 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
WO2003072100A1 (en) * 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US7259175B2 (en) 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
AU2004247355A1 (en) 2003-06-06 2004-12-23 F. Hoffmann-La Roche Ag Aniline derivatives
BRPI0412236A (pt) 2003-07-02 2006-09-12 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa), e utilização desses compostos
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2006071103A1 (en) * 2004-12-31 2006-07-06 Heonjoong Kang Organoselenium containing compounds and their use
EP1856072A4 (en) * 2005-02-25 2009-10-21 Seoul Nat Univ Ind Foundation THIAZOLE DERIVATIVES AS PPAR DELTA LIGANDS AND PROCESSES FOR THE PRODUCTION THEREOF
JP5191744B2 (ja) * 2005-02-25 2013-05-08 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖子活性化受容体デルタリガンドのチアゾール誘導体及びその製造方法
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
US8519145B2 (en) 2006-12-02 2013-08-27 Seoul National University Industry Foundation Aryl compounds as PPAR ligands and their use
BRPI0807023A2 (pt) * 2007-01-08 2014-04-22 Seoul Nat Univ Ind Foundation Composto de tiazol como ligante de ppard e produto farmacêutico, cosmético e alimento saudável dele composto
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
CN102781924A (zh) * 2010-02-25 2012-11-14 首尔大学校产学协力财团 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano

Also Published As

Publication number Publication date
JP2004518702A (ja) 2004-06-24
HK1059925A1 (en) 2004-07-23
DE60124302T2 (de) 2007-05-03
KR20030072571A (ko) 2003-09-15
ZA200304679B (en) 2004-10-04
CY1105915T1 (el) 2011-04-06
IL156436A (en) 2008-06-05
IL156436A0 (en) 2004-01-04
WO2002062774A1 (en) 2002-08-15
SI1343773T1 (sl) 2007-04-30
EP1343773B1 (en) 2006-11-02
MY136685A (en) 2008-11-28
NZ526543A (en) 2004-11-26
EP1343773A1 (en) 2003-09-17
JP4209681B2 (ja) 2009-01-14
PT1343773E (pt) 2007-02-28
HUP0400837A2 (hu) 2004-08-30
ES2274914T3 (es) 2007-06-01
AR035522A1 (es) 2004-06-02
DE60124302D1 (de) 2006-12-14
TWI292759B (en) 2008-01-21
NO20032801D0 (no) 2003-06-19
CZ20031737A3 (cs) 2003-10-15
HUP0400837A3 (en) 2007-11-28
MXPA03005699A (es) 2003-10-06
KR100815022B1 (ko) 2008-03-18
CA2432188A1 (en) 2002-08-15
ATE344253T1 (de) 2006-11-15
BR0116370A (pt) 2003-12-09
CN1252057C (zh) 2006-04-19
DK1343773T3 (da) 2007-02-05
AU2002246713B2 (en) 2004-09-09
CN1527822A (zh) 2004-09-08
PL365797A1 (en) 2005-01-10
NO20032801L (no) 2003-08-04

Similar Documents

Publication Publication Date Title
EG26979A (en) Chemical compounds
GB0004890D0 (en) Chemical compounds
AU4699701A (en) Chemical compounds
GB0004886D0 (en) Chemical compounds
GB0002032D0 (en) Chemical compounds
AU9572301A (en) Chemical compounds
GB0003224D0 (en) Chemical compounds
GB0007934D0 (en) Chemical compounds
GB0005642D0 (en) Chemical compounds
AU7993801A (en) Chemical compounds
GB0002034D0 (en) Chemical compounds
GB0004686D0 (en) Chemical compounds
GB0002033D0 (en) Chemical compounds
GB0007657D0 (en) Chemical compounds
GB0000626D0 (en) Chemical compounds
GB0001346D0 (en) Chemical compounds
GB0001348D0 (en) Chemical compounds
GB0002040D0 (en) Chemical compounds
GB0002036D0 (en) Chemical compounds
GB0007245D0 (en) Chemical compounds
GB0002031D0 (en) Chemical compounds
GB0002041D0 (en) Chemical compounds
GB0002029D0 (en) Chemical compounds
GB0003500D0 (en) Chemical compounds
GB0006977D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)